Oramed Pharmaceuticals (STU:OJU1) Net Income From Continuing Operations : €-25.96 Mil (TTM As of Mar. 2025)

View and export this data going back to 2007. Start your Free Trial

What is Oramed Pharmaceuticals Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Oramed Pharmaceuticals's net income from continuing operations for the three months ended in Mar. 2025 was €-7.07 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2025 was €-25.96 Mil.

Oramed Pharmaceuticals Net Income From Continuing Operations Historical Data

The historical data trend for Oramed Pharmaceuticals's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oramed Pharmaceuticals Net Income From Continuing Operations Chart

Oramed Pharmaceuticals Annual Data

Trend

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Dec22

Dec23

Dec24

Net Income From Continuing Operations

Get a 7-Day Free Trial

-9.73

-19.54

-35.65

4.67

-18.24

Oramed Pharmaceuticals Quarterly Data
	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Net Income From Continuing Operations	Get a 7-Day Free Trial															1.41	8.55	-17.70	-9.74	-7.07

Oramed Pharmaceuticals Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-25.96 Mil.

Oramed Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oramed Pharmaceuticals Inc (STU:OJU1) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

ORMP:USA ORMP:Israel OJU1:Germany

Address

1185 Avenue of the Americas, Third Floor, New York, NY, USA, 10036

Website

https://www.oramed.com

Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.

Oramed Pharmaceuticals Headlines

No Headlines